VIENNALAB - Established innovations in diagnostics

5-Fluorouracil (5-FU) is widely and successfully used for the treatment of solid tumors. In some patients, however, an enzyme variant results in the need of therapy adjustment. The PGX-5FU StripAssay® identifies the most common mutation with therapeutic relevance for 5-FU treatment.

Response to Fluorouracil Therapy

  • 5-FU is rapidly metabolized in the liver, with dihydropyrimidine dehydrogenase (DPD) being the rate-limiting enzyme.
  • Most of the 3-5% of patients not adequately metabolizing 5-FU carry a specific mutation in their DPD gene.
  • While heterozygous patients should receive lower 5-FU doses, homozygous patients should receive alternative chemotherapeutic treatment.
  • Identification of the relevant mutation in DPD and determination of whether a carrier is homozygous or heterozygous for this DPD mutation is crucial for allowing an adequate 5-FU therapy.

Product Details

PGX-5FU StripAssay® ref4-720